Rapamycin in Combination With Low-Dose Aracytin in Elderly Acute Myeloid Leukemia Patients

• Status: Completed
• Trial end date: 2008-06-01
• Target enrollment: 0
• Participant gender: All

Summary

These study is designed to evaluate the tolerability and efficacy of sirolimus (rapamycin) in combination with low-dose aracytin in elderly AML.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Toulouse
• Collaborator: French Innovative Leukemia Organisation
• Treatments: Everolimus; Sirolimus

Criteria

Inclusion Criteria:

• Age > 60 y.

• Informed consent

• de novo or secondary LAM(CML excluded) not elligible for intensive chemotherapy.

• Previously untreated

Exclusion Criteria:

• Renal impairment (serum creatinin >2N)

• Hepatic impairment (TGO ou TGP > 5N), une cholestase (Phosphatases Alcalines or gamma-GT > 5N),bilirubin > 3N

• Blast crisis CML

• Acute Promyelocytic Leukemia